{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"ORR will be calculated for all treated patients for each disease cohort. The corresponding 95% two-sided confidence interval will be derived.","groups":[{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG000","title":"Treatment (Ixazomib Citrate, Rituximab)"}],"populationDescription":"No patients with Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) were enrolled.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"ORR (CR + Very Good PR + PR + Minor Response) in Patients With Waldenstrom Macroglobulinemia (WM)/ Lymphoplasmacytic Lymphoma (LPL)","type":"PRIMARY"}